person · Reporting owner
German Christopher Paul
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Corporate Controller & CAO | May 15, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,888 |
Reported balance
After 2026-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-15 · Exercise / conversion · Acquired 1,687 · Balance 1,888 F1: Includes an aggregate of 201 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 3,237 |
Reported balance
After 2026-05-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-05-15 · Exercise / conversion · Acquired 1,349 · Balance 3,237 |
| Common StockSEC Table I · non-derivative | Direct | 4,643 |
Reported balance
After 2026-05-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-05-15 · Exercise / conversion · Acquired 1,406 · Balance 4,643 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-05-15 · Sale · Disposed 4,643 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.69 · Expires 2035-02-13 | Direct | 3,713 |
Reported balance
After 2026-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-15 · Exercise / conversion · Disposed 1,687 · Balance 3,713 F2: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.23 · Expires 2034-02-15 | Direct | 2,701 |
Reported balance
After 2026-05-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-15 · Exercise / conversion · Disposed 1,349 · Balance 2,701 F3: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.97 · Expires 2033-04-03 | Direct | 2,325 |
Reported balance
After 2026-05-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-15 · Exercise / conversion · Disposed 1,406 · Balance 2,325 F4: The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 201 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.
F2: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
F3: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
F4: The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 19, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,406 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001104659-26-063830 · tm2615084-1_4seq1.xml · derivative · entry 7 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,325 Underlying: Common Stock · 1,406 shares Expires 2033-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,349 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-26-063830 · tm2615084-1_4seq1.xml · derivative · entry 6 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,701 Underlying: Common Stock · 1,349 shares Expires 2034-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,687 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-26-063830 · tm2615084-1_4seq1.xml · derivative · entry 5 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,713 Underlying: Common Stock · 1,687 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4,643 | $92.21 | $428,131.03 |
DisclosureSEC source: 0001104659-26-063830 · tm2615084-1_4seq1.xml · nonDerivative · entry 4 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,406 | $17.97 | $25,265.82 |
DisclosureSEC source: 0001104659-26-063830 · tm2615084-1_4seq1.xml · nonDerivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,349 | $49.23 | $66,411.27 |
DisclosureSEC source: 0001104659-26-063830 · tm2615084-1_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,687 | $56.69 | $95,636.03 |
DisclosureSEC source: 0001104659-26-063830 · tm2615084-1_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 201 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:51 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001104659-26-024750 · tm268127-1_4seq1.xml · derivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,731 Underlying: Common Stock · 1,500 shares Expires 2033-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:51 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,614 | $89.56 | $502,789.84 |
DisclosureSEC source: 0001104659-26-024750 · tm268127-1_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160 F1 · balance_after: Includes 21 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:51 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,500 | $17.97 | $26,955.00 |
DisclosureSEC source: 0001104659-26-024750 · tm268127-1_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 00:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023018 · tm267913-1_4seq1.xml · derivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,162 Underlying: Common Stock · 1,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 1, 2026 and March 1, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 1, 2026 and March 1, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 00:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 342 | $94.94 | $32,469.48 |
DisclosureSEC source: 0001104659-26-023018 · tm267913-1_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,253 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 00:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-023018 · tm267913-1_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 5,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015398 · tm266366-3_4seq1.xml · derivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,215 Underlying: Common Stock · 5,215 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009766 · tm264963-3_4seq1.xml · derivative · entry 4 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,418 Underlying: Common Stock · 1,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009766 · tm264963-3_4seq1.xml · derivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,612 Underlying: Common Stock · 1,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 1,138 | $108.99 | $124,030.62 |
DisclosureSEC source: 0001104659-26-009766 · tm264963-3_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433 F3 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-009766 · tm264963-3_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 36 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 500 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-25-078814 · tm2523328-2_4seq1.xml · derivative · entry 5 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,050 Underlying: Common Stock · 500 shares Expires 2034-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001104659-25-078814 · tm2523328-2_4seq1.xml · derivative · entry 4 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,231 Underlying: Common Stock · 1,000 shares Expires 2033-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,500 | $95.00 | $142,500.00 |
DisclosureSEC source: 0001104659-25-078814 · tm2523328-2_4seq1.xml · nonDerivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 922 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 500 | $49.23 | $24,615.00 |
DisclosureSEC source: 0001104659-25-078814 · tm2523328-2_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,000 | $17.97 | $17,970.00 |
DisclosureSEC source: 0001104659-25-078814 · tm2523328-2_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 850 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-25-067428 · tm2520691-2_4seq1.xml · derivative · entry 6 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,550 Underlying: Common Stock · 850 shares Expires 2034-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001104659-25-067428 · tm2520691-2_4seq1.xml · derivative · entry 5 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,231 Underlying: Common Stock · 2,000 shares Expires 2033-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,850 | $85.00 | $157,250.00 |
DisclosureSEC source: 0001104659-25-067428 · tm2520691-2_4seq1.xml · nonDerivative · entry 4 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 922 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,967 | $76.75 | $150,967.25 |
DisclosureSEC source: 0001104659-25-067428 · tm2520691-2_4seq1.xml · nonDerivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,772 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 850 | $49.23 | $41,845.50 |
DisclosureSEC source: 0001104659-25-067428 · tm2520691-2_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,000 | $17.97 | $35,940.00 |
DisclosureSEC source: 0001104659-25-067428 · tm2520691-2_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,069 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001104659-25-058954 · tm2517859-1_4seq1.xml · derivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,231 Underlying: Common Stock · 1,069 shares Expires 2033-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,069 | $67.19 | $139,016.11 |
DisclosureSEC source: 0001104659-25-058954 · tm2517859-1_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,889 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025 Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,069 | $17.97 | $19,209.93 |
DisclosureSEC source: 0001104659-25-058954 · tm2517859-1_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 21:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 344 | $54.23 | $18,655.12 |
DisclosureSEC source: 0001104659-25-027336 · tm259548-2_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,889 F2 · kind: The sale reported in this Form 4 was effected pursuant to non-Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-027336 · tm259548-2_4seq1.xml · derivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,324 Underlying: Common Stock · 1,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units have vested or will vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 20, 2026 and March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units have vested or will vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 20, 2026 and March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-027336 · tm259548-2_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 635 | $57.22 | $36,334.70 |
DisclosureSEC source: 0001104659-25-015319 · tm257103-3_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,070 F3 · kind: The sale reported in this Form 4 was effected pursuant to non-Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015319 · tm257103-3_4seq1.xml · derivative · entry 5 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,418 Underlying: Common Stock · 1,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-015319 · tm257103-3_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 103 additional shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 5,400 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-25-015319 · tm257103-3_4seq1.xml · derivative · entry 4 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 5,400 shares Expires 2035-02-13 F5 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:45 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 7,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015319 · tm257103-3_4seq1.xml · derivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,225 Underlying: Common Stock · 7,225 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 368 | $41.76 | $15,367.68 |
DisclosureSEC source: 0001104659-24-043249 · tm2410989-1_4seq1.xml · nonDerivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 795 F2 · kind: The sale reported in this Form 4 was effected pursuant to non-Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.55 to $41.76. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2024 Filed Apr 4, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-043249 · tm2410989-1_4seq1.xml · derivative · entry 3 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,487 Underlying: Common Stock · 1,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested or will vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 20, 2026 and March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested or will vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 20, 2026 and March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date. Read SEC document |
| March 20, 2024 Filed Apr 4, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-043249 · tm2410989-1_4seq1.xml · nonDerivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 5,400 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-24-026159 · tm246920-5_4seq1.xml · derivative · entry 2 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 5,400 shares Expires 2034-02-15 F3 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 7,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026159 · tm246920-5_4seq1.xml · derivative · entry 1 German Christopher Paul · CIK 0001260835 · Corporate Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,225 Underlying: Common Stock · 7,225 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.